Comparison of Crinetics Pharmaceuticals Inc. (CRNX) and Novelion Therapeutics Inc. (NASDAQ:NVLN)

As Biotechnology businesses, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Novelion Therapeutics Inc. (NASDAQ:NVLN), are affected by contrast. This especially applies to their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Crinetics Pharmaceuticals Inc. 2.35M 221.48 30.67M -1.14 0.00
Novelion Therapeutics Inc. 135.15M 0.12 107.35M -5.76 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Crinetics Pharmaceuticals Inc. and Novelion Therapeutics Inc.

Profitability

Table 2 shows us the return on equity, net margins and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
Crinetics Pharmaceuticals Inc. -1,305.11% -38.4% -21.7%
Novelion Therapeutics Inc. -79.43% 210.1% -33.2%

Liquidity

Crinetics Pharmaceuticals Inc. has a Current Ratio of 21 and a Quick Ratio of 21. Competitively, Novelion Therapeutics Inc.’s Current Ratio is 0.2 and has 0.2 Quick Ratio. Crinetics Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Novelion Therapeutics Inc.

Analyst Recommendations

The table shown features the ratings and recommendations for Crinetics Pharmaceuticals Inc. and Novelion Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Crinetics Pharmaceuticals Inc. 0 0 1 3.00
Novelion Therapeutics Inc. 0 0 0 0.00

$40 is Crinetics Pharmaceuticals Inc.’s consensus target price while its potential upside is 85.27%.

Institutional and Insider Ownership

The shares of both Crinetics Pharmaceuticals Inc. and Novelion Therapeutics Inc. are owned by institutional investors at 98.4% and 51.2% respectively. Insiders owned 0.3% of Crinetics Pharmaceuticals Inc. shares. Comparatively, 0.2% are Novelion Therapeutics Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Crinetics Pharmaceuticals Inc. -3.56% 9.99% 2.73% -6.04% 0% -15.91%
Novelion Therapeutics Inc. -3.61% -16.67% -13.04% -29.82% -70.66% 42.86%

For the past year Crinetics Pharmaceuticals Inc. has -15.91% weaker performance while Novelion Therapeutics Inc. has 42.86% stronger performance.

Summary

On 6 of the 11 factors Crinetics Pharmaceuticals Inc. beats Novelion Therapeutics Inc.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases. Its product portfolio includes MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; and lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the brand names of JUXTAPID and LOJUXTA. The companyÂ’s orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, in late stage development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.